3-[2-(3,4-dimethoxybenzoyl)-4,5-dimethoxyphenyl]pentan-2-one

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1986-1987

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Non-GLP

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1986

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

Principles of method if other than guideline:

Similar to OECD 423.

GLP compliance:

no

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

3-[2-(3,4-dimethoxybenzoyl)-4,5-dimethoxyphenyl]pentan-2-one

EC Number:

239-479-8

EC Name:

3-[2-(3,4-dimethoxybenzoyl)-4,5-dimethoxyphenyl]pentan-2-one

Cas Number:

15462-91-6

Molecular formula:

C22H26O6

IUPAC Name:

3-[2-(3,4-dimethoxybenzoyl)-4,5-dimethoxyphenyl]pentan-2-one

Test material form:

solid: crystalline

Details on test material:

- Name of test material (as cited in study report): Tetrametoxi-benzofenon
- Molecular formula (if other than submission substance):
- Molecular weight (if other than submission substance):
- Smiles notation (if other than submission substance):
- InChl (if other than submission substance):
- Structural formula attached as image file (if other than submission substance): see Fig.
- Substance type: organic
- Physical state: white crystalline powder
- Analytical purity:
- Impurities (identity and concentrations):
- Composition of test material, percentage of components:
- Isomers composition:
- Purity test date:
- Lot/batch No.:
- Expiration date of the lot/batch:
- Radiochemical purity (if radiolabelling):
- Specific activity (if radiolabelling):
- Locations of the label (if radiolabelling):
- Expiration date of radiochemical substance (if radiolabelling):
- Stability under test conditions: stable
- Storage condition of test material: room temperature
- Other:

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source:
- Age at study initiation:
- Weight at study initiation: 193.00 +/-11 g (male), 159.50 +/-8 g (female)
- Fasting period before study: 18 h
- Housing:
- Diet (e.g. ad libitum):
- Water (e.g. ad libitum):
- Acclimation period:

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 +/- 1.5
- Humidity (%):
- Air changes (per hr):
- Photoperiod (hrs dark / hrs light): 12 h/12 h

IN-LIFE DATES: From: To:

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: 1 % methylcellulose in water

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 1 % methylcellulose
- Amount of vehicle (if gavage):
- Justification for choice of vehicle:
- Lot/batch no. (if required):
- Purity:

MAXIMUM DOSE VOLUME APPLIED: 7100 mg/kg

DOSAGE PREPARATION (if unusual):

CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose:
Dose selection according to Deichmann-Le Blanck.
1 dose, 6-6 animals

Doses:

2600 mg/kg
3600 mg/kg
4250 mg/kg
5000 mg/kg
7100 mg/kg

No. of animals per sex per dose:

Dose selection (approximate LD50 test)
2600mg/kg 2 male/2 female
3600 mg/kg 2 male/2 female
4250 mg/kg 2 male/2 female
5000 mg/kg 2 male/2 female
7100 mg/kg 2 male/2 female

Dose selection (LD50)
5000 mg/kg 6male/6 female

Control animals:

yes

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: 2 h, 4h, 24h, 48 h, 72 h and 7. day, 14. day
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, relative organ weights, histopathology

Results and discussion

Preliminary study:

Dose Male Female
(mg/kg) (dead/alive) (dead/alive)
2600 ( -/2) symptom free survivors (-/2) symptom free survivors
3600 ( -/2) symptom free survivors ( -/2) symptom free survivors
4250 ( -/2) symptom free survivors ( -/2) symptom free survivors
5000 ( -/2) symptom free survivors ( -/2) symptom free survivors
7100 ( -/2) symptom free survivors ( -/2) symptom free survivors

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

approximate LD50

Effect level:

> 5 000 mg/kg bw

Based on:

test mat.

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 5 000 mg/kg bw

Mortality:

No mortality.

Clinical signs:

hampered respiration; lack of exercise after the treatment, which past after 2 hours

Body weight:

No relevant changes. The survaviors body weight gain was similar or higher than the control group.

Gross pathology:

-

Applicant's summary and conclusion

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The substance is not classified as toxic.